Skip to content

Clinical study investigating the effects of NMN/garlic extract supplements on sleep

Clinical study investigating the effects of NMN/garlic extract supplements on sleep - Clinical study investigating the effects of NMN/garlic extract supplements on sleep

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000059201
Enrollment
22
Registered
2025-09-26
Start date
2025-09-30
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Healthy Adults

Interventions

For one week, consume the test food daily between waking and noon. Following the washout period, consume the placebo food daily between waking and noon for one week. On the evening before the test and

Sponsors

Healthcare Systems Co., Ltd.
Lead Sponsor
Institute for Research on Productive Aging
Collaborator
IRPA S&#39
Collaborator
UIMIN Co., Ltd. Bizen Kasei Co., Ltd.
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Persons who received a sufficient explanation of the purpose and contents of the exam, have the capacity to consent, applied with free will with sufficient understanding, and agreed to participate with a written document 2. Japanese adult men and women aged 40 to 65 years at the time of consent. 3. Persons who are attending school, working, or engaged in housework on weekdays and whose daily bedtime and wake-up times do not fluctuate significantly. 4. Persons whose sleep EEG measurements during the screening test show a tendency toward a decrease in total sleep time or the proportion of deep sleep.

Exclusion criteria

Exclusion criteria: 1. Persons who have a severe gastrointestinal, hepatic, renal, cardiovascular, hematological, or endocrine disease, or a suspected malignancy; or have a history of such diseases, are currently hospitalized, or have a present medical history. 2. Persons who have been diagnosed with and received treatment for insomnia. 3. Persons who have been diagnosed with or have a tendency to have sleep apnea syndrome or behavior-induced sleep deprivation syndrome. 4. Persons who have been diagnosed with, or have been diagnosed with, a mood disorder, including depression, and have taken medication. 5. Persons with a BMI of less than 20 or greater than 28. 6. Persons who usually take medicine, specified health food, healthy food and supplements containing NAD intermediate metabolites (complex vitamins, nicotinamide mononucleotide (NMN)) 7. Persons who usually take medicine, specified health food, healthy food and supplements that may affect sleep. 8. Persons who cannot avoid consuming alcohol or caffeine on the day of the sleep EEG measurement. 9. Persons who consume excessive alcohol.* 10. Persons whose usual bed time is less than 6 hours. 11. Persons working shifts, night shifts, or heavy labor. 12. Persons who are breastfeeding, pregnant, or planning or hoping to become pregnant during the study period. 13. Persons living with a caregiver. 14. Persons who cannot sleep alone in a bed or futon during the study period (sleeping with one or more other persons in the same room is permissible). 15. Subjects who are allergic to the standard or test foods. 16. Persons who have participated in other tests within the first month before the start of the test, or those who intend to participate in another exam after consenting to this exam 17. Persons who were judged as inappropriate for study participants by the principal investigator *: The standard for excessive consumption is 3 times a week, 1 go (equivalent to 1 cup of sake) or more.

Design outcomes

Primary

MeasureTime frame
Sleep EEG

Secondary

MeasureTime frame
Plasma NAD+ synthesis-related component concentrations Plasma NAD+ synthesis-related activity OSA Sleep Questionnaire MA Version Blood Biochemistry Tests Blood pressure Pulse rate

Countries

Japan

Contacts

Public ContactHirohito Ishikawa

Healthcare Systems Co., Ltd. Clinical Research Department

ishikawa@hc-sys.jp0368092722

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026